CRISPR Therapeutics reports widening losses and declining revenue amid transition to commercial partnerships in gene-editing therapies.
CRISPR Therapeutics AG (NASDAQ:CRSP) reported a net loss of $581.6 million for its 2025 fiscal year, widening from prior periods as revenue from grants fell to $3.5 million. The company’s sole commercial partner, Vertex Pharmaceuticals, provided $35 million in upfront payments the previous year, highlighting reliance on a single revenue stream.
The company’s net margin plunged to negative 16,570%, reflecting high research and development costs and limited commercial sales. CRISPR Therapeutics focuses on hemoglobinopathy treatments like CASGEVY, but its financials underscore the challenges of scaling gene-editing therapies.
Investors face a choice between CRISPR’s commercial partnerships and competitors like Editas Medicine (NASDAQ:EDIT), which pursues in vivo gene editing with a different risk profile.